FDA PMA FDA Class 3 Approved 🇺🇸 United States

System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy

PMA: P970008 · Supplement: S030 · Decision Mar 20, 2006
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy
Trade Name
UROLOGIX TARGIS SYSTEM
PMA Number
P970008
Supplement Number
S030
Device Class
FDA Class 3
Product Code
MEQ
Generic Name
System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Medical Specialty
Unknown
Advisory Committee
Gastroenterology, Urology
Decision
Approved
Decision Code
APPR
Decision Date
March 20, 2006
Date Received
November 21, 2005
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR UPGRADES TO THE TARGIS SYSTEM. THESE CHANGES INCLUDE IMPROVED APPEARANCE (WHICH REQUIRED REPLACING THE CONTROL UNIT EXTERIOR PANELS AND MOVING THE USER CONTROLS), IMPROVED ELECTROMAGNETIC COMPATIBILITY (EMC), AND OTHER COMPONENT AND MANUFACTURING MODIFICATIONS DUE TO COMPONENT OBSOLESCENCE.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MEQ System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy